|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsieh TC and Wu JM: Resveratrol:
Biological and pharmaceutical properties as anticancer molecule.
Biofactors. 36:360–369. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frazzi R, Valli R, Tamagnini I, Casali B,
Latruffe N and Merli F: Resveratrol-mediated apoptosis of hodgkin
lymphoma cells involves SIRT1 inhibition and FOXO3a
hyperacetylation. Int J Cancer. 132:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Zhu W, Li J, Liu M and Wei M:
Resveratrol suppresses the STAT3 signaling pathway and inhibits
proliferation of high glucose-exposed HepG2 cells partly through
SIRT1. Oncol Rep. 30:2820–2828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang Y and Nicholl MB: Sirtuin 1 in
malignant transformation: Friend or foe? Cancer Lett. 306:10–14.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buhrmann C, Shayan P, Popper B, Goel A and
Shakibaei M: Sirt1 is required for resveratrol-mediated
chemopreventive effects in colorectal cancer cells. Nutrients.
8:1452016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu Z and Tindall DJ: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu MH, Lin XL, Li J, He J, Tan TP, Wu SJ,
Yu S, Chen L, Liu J, Tian W, et al: Resveratrol induces apoptosis
through modulation of the Akt/FoxO3a/Bim pathway in HepG2 cells.
Mol Med Rep. 13:1689–1694. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shankar S, Chen Q and Srivastava RK:
Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to
enhance antiangiogenic effects of EGCG through activation of FOXO
transcription factor. J Mol Signal. 3:72008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tzivion G, Dobson M and Ramakrishnan G:
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins.
Biochim Biophys Acta. 1813:1938–1945. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hussain AR, Uddin S, Bu R, Khan OS, Ahmed
SO, Ahmed M and Al-Kuraya KS: Resveratrol suppresses constitutive
activation of AKT via generation of ROS and induces apoptosis in
diffuse large B cell lymphoma cell lines. PLoS One. 6:e247032011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
14
|
Lahoz A and Hall A: DLC1: A significant
GAP in the cancer genome. Genes Dev. 22:1724–1730. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scholz RP, Regner J, Theil A, Erlmann P,
Holeiter G, Jähne R, Schmid S, Hausser A and Olayioye MA: DLC1
interacts with 14-3-3 proteins to inhibit RhoGAP activity and block
nucleocytoplasmic shuttling. J Cell Sci. 122:92–102. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong CM, Yam JW, Ching YP, Yau TO, Leung
TH, Jin DY and Ng IO: Rho GTPase-activating protein deleted in
liver cancer suppresses cell proliferation and invasion in
hepatocellular carcinoma. Cancer Res. 65:8861–8868. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan BZ, Jefferson AM, Baldwin KT,
Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a
tumor suppressor gene in human non-small cell lung carcinomas.
Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Communal C, Sumandea M, de Tombe P, Narula
J, Solaro RJ and Hajjar RJ: Functional consequences of caspase
activation in cardiac myocytes. Proc Natl Acad Sci USA. 99:pp.
6252–6256. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et
al: Stress-dependent regulation of FOXO transcription factors by
the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao H, Ho PC, Lo YH, Espejo A, Bedford
MT, Hung MC and Wang SC: Interaction of proliferation cell nuclear
antigen (PCNA) with c-Abl in cell proliferation and response to DNA
damages in breast cancer. PLoS One. 7:e294162012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu H, Liang X, Fang Y, Qin X, Zhang Y and
Liu J: Resveratrol inhibits hypoxia-induced metastasis potential
enhancement by restricting hypoxia-induced factor-1 alpha
expression in colon carcinoma cells. Biomed Pharmacother.
62:613–621. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aziz MH, Nihal M, Fu VX, Jarrard DF and
Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma
LNCaP cells is mediated via modulation of phosphatidylinositol
3′-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther.
5:1335–1341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu
HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12
cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a
pathway. Cell Mol Neurobiol. 35:513–522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niquet J and Wasterlain CG: Bim, Bad and
Bax: A deadly combination in epileptic seizures. J Clin Invest.
113:960–962. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaushal GP, Kaushal V, Hong X and Shah SV:
Role and regulation of activation of caspases in cisplatin-induced
injury to renal tubular epithelial cells. Kidney Int. 60:1726–1736.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Q, Wang B, Zang W, Wang X, Liu Z, Li
W and Jia J: Resveratrol inhibits the growth of gastric cancer by
inducing G1 phase arrest and senescence in a Sirt1-dependent
manner. PLoS One. 8:e706272013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chae HD and Broxmeyer HE: SIRT1 deficiency
downregulates PTEN/JNK/FOXO1 pathway to block reactive oxygen
species-induced apoptosis in mouse Embryonic stem cells. Stem Cells
Dev. 20:1277–1285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ikenoue T, Inoki K, Zhao B and Guan KL:
PTEN acetylation modulates its interaction with PDZ domain. Cancer
Res. 68:6908–6912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang G, Wang JJ, To TS, Zhao HF and Wang
J: Role of SIRT1-mediated mitochondrial and Akt pathways in
glioblastoma cell death induced by Cotinus coggygria flavonoid
nanoliposomes. Int J Nanomedicine. 10:5005–5023. 2015.PubMed/NCBI
|
|
33
|
Zhou X, Thorgeirsson SS and Popescu NC:
Restoration of DLC-1 gene expression induces apoptosis and inhibits
both cell growth and tumorigenicity in human hepatocellular
carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li G, Du X, Vass WC, Papageorge AG, Lowy
DR and Qian X: Full activity of the deleted in liver cancer 1
(DLC1) tumor suppressor depends on an LD-like motif that binds
talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA.
108:pp. 17129–17134. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qian X, Li G, Asmussen HK, Asnaghi L, Vass
WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG and Lowy DR:
Oncogenic inhibition by a deleted in liver cancer gene requires
cooperation between tensin binding and Rho-specific
GTPase-activating protein activities. Proc Natl Acad Sci USA.
104:pp. 9012–9017. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maddox AS and Burridge K: RhoA is required
for cortical retraction and rigidity during mitotic cell rounding.
J Cell Biol. 160:255–265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim TY, Lee JW, Kim HP, Jong HS, Kim TY,
Jung M and Bang YJ: DLC-1, a GTPase-activating protein for Rho, is
associated with cell proliferation, morphology, and migration in
human hepatocellular carcinoma. Biochem Biophys Res Commun.
355:72–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scholz RP, Gustafsson JO, Hoffmann P,
Jaiswal M, Ahmadian MR, Eisler SA, Erlmann P, Schmid S, Hausser A
and Olayioye MA: The tumor suppressor protein DLC1 is regulated by
PKD-mediated GAP domain phosphorylation. Exp Cell Res. 317:496–503.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ko FC, Chan LK, Sze KM, Yeung YS, Tse EY,
Lu P, Yu MH, Ng IO and Yam JW: PKA-induced dimerization of the
RhoGAP DLC1 promotes its inhibition of tumorigenesis and
metastasis. Nat Commun. 4:16182013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hers I, Wherlock M, Homma Y, Yagisawa H
and Tavaré JM: Identification of p122RhoGAP (deleted in liver
cancer-1) Serine 322 as a substrate for protein kinase B and
ribosomal S6 kinase in insulin-stimulated cells. J Biol Chem.
281:4762–4770. 2006. View Article : Google Scholar : PubMed/NCBI
|
